Melanoma had the highest levels of MAPK activity relative to other tissue types (measured by median MPAS) in our study, consistent with the robust clinical activity of BRAF and MEK1/2 inhibitors observed in this indication (Fig. 2a). The gene discussed is MAP2K1; the disease is melanoma.